Biotech Derivatives Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Derivatives

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LLCF who wrote ()	6/28/2000 8:28:00 PM
From: scott_jiminez	of 555

'With special emphasis on companies where the potential impact of upcoming events....' With that statement in the bylaws of this thread, I don't feel nearly as consumed by guilt in posting this patently spammish message. I've had some decent returns of late with the warrants for Hypertension Diagnostics (HDII; warrants HDIIW). Here are the warrant terms: Each Class A Warrant entitles the holder to purchase one share at an exercise price of $5.50 per Warrant, subject to adjustment. The Class A Warrants are subject to redemption by the Company for $.01 per Warrant at any time commencing October 21, 1998, provided that the closing bid price of the shares exceeds $6.50 (subject to adjustment) for 14 consecutive trading days. The Class A Warrants expire on July 22, 2002. (no guarantees these terms have not been altered) While the call terms are stringent, the stock has been on a roll. In light of the news release today regarding submission of additional data to the FDA for the company's 'profilor' (see my post on the HDII thread), this derivative would appear to warrant additional DD by participants in this forum.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next